Mood stabilizers in the treatment of juvenile bipolar disorder. Advances and controversies.
Controlled studies of mood stabilizer (mono and combination) therapy are needed in children and adolescents to develop safe and effective treatment strategies for a disorder that now has a cohort and that carries a high human and economic cost. Through the use of a variety of diagnostic instruments and novel outcome measures, we may continue to refine DSM categories into more sensitive and specific diagnostic constructs. In addition, identification of neurobiologic and genetic markers for early-onset BPD, ADHD, CD, and IED could provide powerful tools in the process of breaking down phenotypes and establishing biologic predictors of targeted pharmacologic interventions in the face of new drug developments.
Davanzo
P A
PA
Department of Psychiatry, University of California Los Angeles, USA. pdavanzo@mednet.ucla.edu
McCracken
J T
JT
D000293:Adolescent; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D010641:Phenotype; D016896:Treatment Outcome; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D018692:Antimanic Agents; D016651:Lithium Carbonate; D002220:Carbamazepine; D014635:Valproic Acid